To further study the potential use of PTC-209 as an anti-MM agent, we investigated the anti-MM effects of PTC-209 in combinatorial epigenetic regimens in MM cell lines and malignant CD138+ primary cells. The gene discussed is SDC1; the disease is Miyoshi myopathy.